Amgen is back in court and this time it s suing FDA. Amgen filed a complaint, posted on FDA Law Blog , on May 25, 2017 after FDA denied the company six months of pediatric exclusivity under the Best Pharmaceuticals for Children Act (BPCA), for its secondary hyperparathyroidism treatment SensiOriginal Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.